Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

04-142023

Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting

GUANGZHOU, CHINA, April 14, 2023 – Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, tod...
03-132023

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...
03-082023

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...

上一页 ···15 16 17 18 19 ··· 下一页